Biotechnology and genomics equities are showing modest signs of life this year following dismal showings in 2022. The good news for long-term investors is that there could well be much more to come, particularly in the genomics arena. Resurgent equities in that space could stir renewed interest in exchange traded funds, including the ARK Genomic [...] The post Genomics Outlook for Disruption Is Rising appeared first on ETF Trends .